Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - PA: Inst of Nutrition, Metabolism and Diabetes -Bridge Funding

University of Toronto

$99,395.00

Role and mechanism of action of the intestinotrophic hormone, glucagon-like peptide-2, in colonic growth and neoplasia

FY 2008-09

Summary
The Canadian Cancer Society has estimated that there will be over 21,000 new cases of colorectal cancer in 2008, as well as ~9,000 deaths due to this disease, making colon cancer the 2nd leading cause of cancer-related illness and death in Canada. Most colon cancers in humans are not genetic, and likely arise as a result of environmental factors, including dietary nutrients and intestinal inflammation. Interestingly, these risk factors for colon cancer are associated with enhanced circulating levels of the intestinal hormone, glucagon-like peptide-2 (GLP-2). My laboratory has had a long-standing interest in the actions of GLP-2 to increase normal intestinal growth, and we now have strong preliminary data demonstrating that GLP-2 also increases development of colon cancer in mice, while preventing the actions of GLP-2 reduces cancer in these animals. To better understand the role of GLP-2 in colon cancer, as well to develop new approaches to prevent colon cancer, we will now investigate the effects of GLP-2 using a variety of animal models, and will use a newly-developed cell-based approach to determine how these effects of GLP-2 are exerted. Together, these studies will enhance our understanding of the role of GLP-2 in colon cancer.
Program
Operating Grant - PA: Inst of Nutrition, Metabolism and Diabetes -Bridge Funding
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
183255
Name
Brubaker Patricia L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Endocrinology
Projecttitle
Role and mechanism of action of the intestinotrophic hormone, glucagon-like peptide-2, in colonic growth and neoplasia
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$99,395
Cihrequipment2
$0
Programname2
Operating Grant - PA: Inst of Nutrition, Metabolism and Diabetes -Bridge Funding
Keyworddelim
Cancer; Glucagon-Like Peptide-2; Growth; Hormone; Intestine
Abstract
The Canadian Cancer Society has estimated that there will be over 21,000 new cases of colorectal cancer in 2008, as well as ~9,000 deaths due to this disease, making colon cancer the 2nd leading cause of cancer-related illness and death in Canada. Most colon cancers in humans are not genetic, and likely arise as a result of environmental factors, including dietary nutrients and intestinal inflammation. Interestingly, these risk factors for colon cancer are associated with enhanced circulating levels of the intestinal hormone, glucagon-like peptide-2 (GLP-2). My laboratory has had a long-standing interest in the actions of GLP-2 to increase normal intestinal growth, and we now have strong preliminary data demonstrating that GLP-2 also increases development of colon cancer in mice, while preventing the actions of GLP-2 reduces cancer in these animals. To better understand the role of GLP-2 in colon cancer, as well to develop new approaches to prevent colon cancer, we will now investigate the effects of GLP-2 using a variety of animal models, and will use a newly-developed cell-based approach to determine how these effects of GLP-2 are exerted. Together, these studies will enhance our understanding of the role of GLP-2 in colon cancer.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brubaker, Patricia L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,395~ $0~